Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | AOC2 | O75106 | 5/20 | 0.43 |
| ▸ | MAOA | P21397 | 5/20 | 0.43 |
| ▸ | MAOB | P27338 | 5/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31621993 | 0.98 | SIGMAR1 (0.51) | SIGMAR1HTR1AOPRM1OPRL1KCNH2 | |
| Hydrochloric Acid SCHEMBL9692517 | 0.98 | SIGMAR1 (0.51) | SIGMAR1HTR1AOPRM1OPRL1KCNH2 | |
| SCHEMBL9692392 | 0.86 | SIGMAR1 (0.50) | SIGMAR1HTR1AOPRM1OPRL1KCNH2 | |
| Hydrochloric Acid SCHEMBL9692445 | 0.84 | SIGMAR1 (0.49) | SIGMAR1HTR1AOPRM1OPRL1KCNH2 | |
| SCHEMBL441013 | 0.82 | CA2 (0.53) | HTR1ACA2NISCH | |
| SCHEMBL13572976 | 0.81 | SIGMAR1 (0.52) | SIGMAR1HTR1AOPRM1OPRL1KCNH2 | |
| SCHEMBL8354157 | 0.81 | SIGMAR1 (0.52) | SIGMAR1HTR1AOPRM1OPRL1KCNH2 | |
| SCHEMBL13572973 | 0.81 | SIGMAR1 (0.52) | SIGMAR1HTR1AOPRM1OPRL1KCNH2 | |
| SCHEMBL20864244 | 0.81 | SIGMAR1 (0.56) | SIGMAR1HTR1AOPRM1OPRL1KCNH2 | |
| SCHEMBL2247241 | 0.81 | SIGMAR1 (0.52) | SIGMAR1HTR1AOPRM1OPRL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240009169-A9 | PPARG Modulators for the Treatment of Osteoporosis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-01-11 | — | — | US | disclosed |
| US-20230072933-A1 | PPARG Modulators for the Treatment of Osteoporosis | SCRIPPS RESEARCH INST (US) | 2023-03-09 | — | — | US | disclosed |
| US-11173144-B2 | Adrenergic receptor modulating compounds and methods of using the same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-11-16 | — | — | US | disclosed |
| US-10744117-B2 | PPARG modulators for the treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200237724-A1 | ADRENERGIC RECEPTOR MODULATING COMPOUNDS AND METHODS OF USING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2020-07-30 | — | — | US | disclosed |
| US-20180369196-A1 | PPARG Modulators for the Treatment of Osteoporosis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2018-12-27 | — | — | US | disclosed |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-07-10 | — | — | US | disclosed |
| WO-2017197324-A1 | ADRENERGIC RECEPTOR MODULATING COMPOUNDS AND METHODS OF USING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-11-16 | — | — | WO | disclosed |
| US-20170035730-A1 | PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2017-02-09 | — | — | US | disclosed |
| WO-2015161108-A1 | PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-10-22 | — | — | WO | disclosed |
| CN-1024667-C | process for preparing substituted aminomethyl tetralins and substituted aminomethyl hydrogenated benzopyrans and their salts | BAYER AG (DE) | 1994-05-25 | — | — | CN | disclosed |
| EP-0352613-B1 | Substituted amino methyl tetralines, and their heterocyclic analogous compounds | BAYER AG (DE) | 1994-04-20 | — | — | EP | disclosed |
| US-5300523-A | Binding serotonin receptors, treating nervous system disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1994-04-05 | — | — | US | disclosed |
| US-5137901-A | For binding 5-HT 1 receptors; treating central nervous system disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-11 | — | — | US | disclosed |
| US-5112855-A | Nootropic Agents | CIBA-GEIGY CORPORATION (US) | 1992-05-12 | — | — | US | disclosed |
| EP-0252005-B1 | HYDROGENATED 1-BENZOOXACYCLOALKYL-PYRIDINE CARBOXYLIC-ACID COMPOUNDS | CIBA-GEIGY AG (CH) | 1991-07-10 | — | — | EP | disclosed |
| US-4957928-A | NOOTROPIC AGENTS, COGNITION ACTIVATORS | CIBA-GEIGY CORPORATION (US) | 1990-09-18 | — | — | US | disclosed |
| CN-1039809-A | The aminomethyl tetraline that replaces and the preparation of heterocycle homologue thereof | BAYER AG (DE) | 1990-02-21 | — | — | CN | disclosed |
| EP-0352613-A2 | Substituted amino methyl tetralines, and their heterocyclic analogous compounds | BAYER AG (DE) | 1990-01-31 | — | — | EP | disclosed |
| EP-0252005-A1 | Hydrogenated 1-benzooxacycloalkyl-pyridine carboxylic-acid compounds | CIBA-GEIGY AG (CH) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200237724-A1 | ADRENERGIC RECEPTOR MODULATING COMPOUNDS AND METHODS OF USING THE SAME | ADRB1, ADRB2, ADRA1B | SIGMAR1 171/4885HTR1A 115/4885OPRM1 125/4885 |
| US-20170035730-A1 | PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS | PPARG, PPARA, PPARD | SIGMAR1 3856/4885HTR1A 2199/4885OPRM1 2291/4885 |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | PPARG, PPARA, PPARD | SIGMAR1 3856/4885HTR1A 2199/4885OPRM1 2291/4885 |
| US-11173144-B2 | Adrenergic receptor modulating compounds and methods of using the same | ADRB1, ADRB2, ADRA1B | SIGMAR1 171/4885HTR1A 115/4885OPRM1 125/4885 |
| US-20230072933-A1 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | SIGMAR1 3817/4885HTR1A 2252/4885OPRM1 2286/4885 |
| US-20180369196-A1 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | SIGMAR1 3817/4885HTR1A 2252/4885OPRM1 2286/4885 |
| US-10744117-B2 | PPARG modulators for the treatment of osteoporosis | PPARG, PPARA, PPARD | SIGMAR1 3817/4885HTR1A 2252/4885OPRM1 2286/4885 |
| US-20240009169-A9 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | SIGMAR1 3817/4885HTR1A 2252/4885OPRM1 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.